bemcentinib targets and binds to the intracellular catalytic kinase domain of axl receptor tyrosine kinase and inhibits its activity. increase in axl function has been linked to key mechanisms of drug resistance and immune escape by tumor cells, leading to aggressive metastatic cancers. in addition, bgb324 enhances sensitivity to various therapies including chemotherapy, immunotherapy and several targeted therapeutics.